


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On

TOWNSEND and TOWNSEND and CREW LLP

By:



PATENT
Attorney Docket No.: 02558B-059130US
Customer No.: 20350

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LIN *et al.*

Application No.: 10/766,096

Filed: January 27, 2004

For: METHOD AND FORMULATION
FOR LYOPHILIZING CULTURED
HUMAN CELLS TO PRESERVE RNA
AND DNA CONTAINED IN CELLS
FOR USE IN MOLECULAR BIOLOGY
EXPERIMENTS

Confirmation No. 3204

Examiner: Not yet assigned

Art Unit: Not yet assigned

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed June 15, 2004, Applicants submit that the computer-readable form in the instant application is identical with the Sequence Listing submitted on November 23, 1999 for Application No. 08/884,029, with a filing date of June 27, 1997. In accordance with 37 C.F.R. § 1.821(e), please use the last-filed computer-readable form filed in Application No. 08/884,029 as the computer-readable form for the instant application. A paper copy of the Sequence Listing from Application No.

Appl. No. 10/766,096
Amdt. dated July 9, 2004
Reply to Notice to Comply of June 17, 2004

PATENT

08/884,029 is submitted herewith. The information in the paper copy of the Sequence Listing is identical to that which is in the computer readable form submitted on November 23, 1999, as required under 37 C.F.R. § 1.821(f).

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that will be used for the instant application.

Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

Amendments to the Specification begin on page 3 of this paper.

Remarks begin on page 4 of this paper.